Safety and Effectiveness of Drug-Eluting and Bare-Metal Stents for Patients With Off- and On-Label Indications

Journal of the American College of Cardiology

Volumn 53, Issue 19, 2009, Pages 1773-1782

  Ko, Dennis T ^a,b   Chiu, Maria ^b   Guo, Helen ^b   Austin, Peter C ^b   Goeree, Ron ^c   Cohen, Eric ^a   Labinaz, Marino ^d,e   Tu, Jack V ^a,b  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d Programs for Assessment of Technology in Health Research Institute   (Canada)

^e UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

cardiovascular outcomes; drug eluting stent; off label indication

Indexed keywords

ADULT; AGED; ARTICLE; COHORT ANALYSIS; DRUG ELUTING STENT; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVASCULARIZATION; RISK ASSESSMENT; SCORING SYSTEM; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; COHORT STUDIES; CONFIDENCE INTERVALS; CORONARY RESTENOSIS; DATABASES AS TOPIC; DRUG TOXICITY; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; ONTARIO; RISK FACTORS;

EID: 65349134833     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.01.059     Document Type: Article

References (27)

1. Stone G.W., Ellis S.G., Cox D.A., et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 350 (2004) 221-231
2. Moses J.W., Leon M.B., Popma J.J., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349 (2003) 1315-1323
3. Babapulle M.N., Joseph L., Belisle P., Brophy J.M., and Eisenberg M.J. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 364 (2004) 583-591
4. Iakovou I., Schmidt T., Bonizzoni E., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293 (2005) 2126-2130
5. Bavry A.A., Kumbhani D.J., Helton T.J., Borek P.P., Mood G.R., and Bhatt D.L. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med 119 (2006) 1056-1061
6. Pfisterer M., Brunner-La Rocca H.P., Buser P.T., et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 48 (2006) 2584-2591
7. Lagerqvist B., James S.K., Stenestrand U., Lindback J., Nilsson T., and Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356 (2007) 1009-1019
8. Spaulding C., Daemen J., Boersma E., Cutlip D.E., and Serruys P.W. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 989-997
9. Mauri L., Hsieh W.H., Massaro J.M., Ho K.K., D'Agostino R., and Cutlip D.E. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356 (2007) 1020-1029
10. Stone G.W., Moses J.W., Ellis S.G., et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356 (2007) 998-1008
11. Kastrati A., Mehilli J., Pache J., et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 1030-1039
12. Beohar N., Davidson C.J., Kip K.E., et al. Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA 297 (2007) 1992-2000
13. Win H.K., Caldera A.E., Maresh K., et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA 297 (2007) 2001-2009
14. Marroquin O.C., Selzer F., Mulukutla S.R., et al. A comparison of bare-metal and drug-eluting stents for off-label indications. N Engl J Med 358 (2008) 342-352
15. Tu J.V., Bowen J., Chiu M., et al. Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med 357 (2007) 1393-1402
16. CYPHER sirolimus-eluting stent: essential prescribing information. http://cordis.com Accessed June 1, 2008.
17. TAXUS Express 2 stent system: directions for use. http://www.taxus-stent.com Accessed June 1, 2008.
18. Quan H., Sundararajan V., Halfon P., et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43 (2005) 1130-1139
19. Austin P.C., Grootendorst P., and Anderson G.M. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med 26 (2007) 734-753
20. Austin P.C., and Mamdani M.M. A comparison of propensity score methods: a case-study estimating the effectiveness of post-AMI statin use. Stat Med 25 (2006) 2084-2106
21. Stone G.W., Ellis S.G., Colombo A., et al. Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation. Circulation 115 (2007) 2842-2847
22. Applegate R.J., Sacrinty M.T., Kutcher M.A., et al. "Off-label" stent therapy 2-year comparison of drug-eluting versus bare-metal stents. J Am Coll Cardiol 51 (2008) 607-614
23. Groeneveld P.W., Matta M.A., Greenhut A.P., and Yang F. Drug-eluting compared with bare-metal coronary stents among elderly patients. J Am Coll Cardiol 51 (2008) 2017-2024
24. Mauri L., Silbaugh T.S., Wolf R.E., et al. Long-term clinical outcomes after drug-eluting and bare-metal stenting in Massachusetts. Circulation 118 (2008) 1817-1827
25. DES fall from GRACE in STEMI: Patients face more than fourfold higher risk of death than bare-metal-stent-treated patients. http://www.theheart.org/article/810647.do Accessed June 1, 2008.
26. HORIZONS AMI: Drug-eluting stent safe and effective in the setting of STEMI. http://www.theheart.org//editorial-program/911985.do Accessed November 24, 2008.
27. Mauri L., Silbaugh T.S., Garg P., et al. Drug-eluting or bare-metal stents for acute myocardial infarction. N Engl J Med 359 (2008) 1330-1342